Glucagon-Like Peptide 1 and Gastric Inhibitory Polypeptide: Potential Applications in Type 2 Diabetes Mellitus

ISSN： 1173-8804

Source： BioDrugs, Vol.17, Iss.2, 2003-01, pp. : 93-102

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Gastric Inhibitory Polypeptide Analogues: Do They Have a Therapeutic Role in Diabetes Mellitus Similar to That of Glucagon-Like Peptide-1?

By Holst J.J.

BioDrugs, Vol. 16, Iss. 3, 2002-01 ,pp. : 175-181

Adis International

Access to resources Recommend Favorite

Pathophysiology of Immune-Mediated (Type 1) Diabetes Mellitus: Potential for Immunotherapy

By Abel M. Krokowski M.

BioDrugs, Vol. 15, Iss. 5, 2001-05 ,pp. : 291-301

Adis International

Access to resources Recommend Favorite

Spotlight on Insulin Detemir in Type 1 and 2 Diabetes Mellitus

By Chapman Therese M. Perry Caroline M.

BioDrugs, Vol. 19, Iss. 1, 2005-01 ,pp. : 67-69

Adis International

Access to resources Recommend Favorite

Long-Acting GLP-1 Analogs for the Treatment of Type 2 Diabetes Mellitus

By Vilsbøll Tina Knop Filip K.

BioDrugs, Vol. 22, Iss. 4, 2008-01 ,pp. : 251-257

Adis International

Access to resources Recommend Favorite

Iliopsoas abscess in adolescents with type 1 diabetes mellitus

Clinical Case Reports, Vol. 3, Iss. 7, 2015-07 ,pp. : 638-642

John Wiley & Sons Inc

Access to resources Recommend Favorite